# PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jul 31, 2013

- Company: [PharmaCyte Biotech, Inc.](/companies/pmcb.md) (CIK 1157075)
- Form: 10-Q
- Filed: 2013-09-16
- Accepted by EDGAR: Sep 13, 2013, 18:33 ET
- Period: 2013-07-31
- Accession: 0001157075-13-000015
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1157075/000115707513000015/nvlx-07312013x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1157075/000115707513000015/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-07-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-05-01 to 2013-07-31 | $0 | us-gaap:Revenues |
| Gross profit | 3 months, 2013-05-01 to 2013-07-31 | $0 | us-gaap:GrossProfit |
| Operating income | 3 months, 2013-05-01 to 2013-07-31 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-05-01 to 2013-07-31 | $10.4k | us-gaap:InterestExpense |
| Net income | 3 months, 2013-05-01 to 2013-07-31 | −$4.7m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months, 2013-05-01 to 2013-07-31 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months, 2013-05-01 to 2013-07-31 | −$159.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2013-07-31 | $206.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-07-31 | $1.8m | us-gaap:AssetsCurrent |
| Total assets | at 2013-07-31 | $3.4m | us-gaap:Assets |
| Current liabilities | at 2013-07-31 | $994.2k | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2013-07-31 | $994.2k | us-gaap:Liabilities |
| Shareholders' equity | at 2013-07-31 | $1.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 3,128 characters.

*The following discussion may contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to, any factors discussed in this section as well as factors described in “Part II, Item 1A – Risk Factors” of this Quarterly Report, and in the Risk Factors section of our Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on July 29, 2012, and amended on July 30, 2013.*

### RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JULY 31, 2013 AND 2012

### REVENUES

There was no revenue generated during the three months ended July 31, 2013. Revenues decreased from $6,626 to $0 from the three months ended July 31, 2012 compared to the same period in 2013 as a result of multiple factors. In 2012, we made a decision to discontinue the sale of Cinnergen because the costs of, marketing and maintaining Cinnergen was in excess of the revenues generated. The prior year's revenue was derived solely from the sale of Cinnergen, which sales occurred even in the absence of substantial marketing efforts. We instead allocated funds toward the parent company, so that we could acquire the necessary components and personnel for its biotechnology operations to move forward.

### SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

The overall general and administrative expenses during the three months ended July 31, 2013 compared to the three months ended July 31, 2012, decreased $110,800 to $119,206 from $230,006 in the prior period. The decrease can be contributed to an overall decrease in spending on marketing, investor relations and other consulting services.

For the three months ended July 31, 2013 compensation expense increased $1,020,946 to $1,202,127 from $181,181 for the same period in the prior year. The increase is a result of an overall increase in the share price of the shares of Common Stock being issued for compensation. In addition, during the current quarter the Company issued common stock to Directors of the Company valued at $480,000.

During the three months ended July 31, 2013, there was an increase of $4,155,850 in the net loss to $4,666,367 compared to $510,517 in the prior period. The increase in the loss from operations of $861,905 to $1,400,691 combined with a loss on settlement of debt of $3,973,795 resulted in the large increase in the net loss for the period.

### LIQUIDITY AND CAPITAL RESOURCES

By adjusting the Company’s operations and through the proceeds from private placement transactions with new investors and existing shareholders, the Company has been able to maintain sufficient capital resources to meet projected cash flow needs. Failure by the Company to generate sufficient liquidity from operations or in raising sufficient capital resources on acceptable terms may have a materially adverse effect on the Company’s business, results of operations, liquidity and financial condition.

We have no off-balance sheet arrangements, special purpose entities, financing partnerships or guarantees.

## Controls and procedures

As filed, 1,283 characters.

### Evaluation of Disclosure Controls and Procedures.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer (our principal executive officer) of the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 (“Exchange Act”) Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our Chief Executive Officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Controls Over Financial Reporting.

There have been no changes to our internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the fiscal quarter ended July 31, 2013 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 261 characters.

There have been no material changes in the Company’s risk factors from those previously disclosed in the Company’s Form 10-K/A for the year ended April 30, 2013.

No New Risk Factors Are Hereby Submitted. See the April 30, 2013 Form 10-K/A for All Risk Factors.

Filed Sep 16, 2013.
Source: SEC EDGAR, the filing index for accession 0001157075-13-000015. Last ingested by Listed: Nov 14, 2026, 20:52 ET. No prices; not investment advice.
